Psychedelic and ketamine research trials in Spain
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
7 registered studies are counted in Spain. By compound: 3 MDMA, 1 DMT, 1 ayahuasca, 2 ketamine and 1 ibogaine. By registry status: 1 recruiting, 1 not yet recruiting, 3 completed and 2 status not reported. By phase: 3 phase 1, 2 phase 2, 1 phase 3 and 1 not applicable. Reported start years run from 2003 (earliest) to 2025 (latest). Studies are linked to 6 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
2 of the 7 counted studies are listed in the registry as recruiting (1) or not yet recruiting (1), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression | NCT07422519 | Recruiting | Not applicable | 2025-09-18 | Hospital Universitari Vall d'Hebron Research Institute, Barcelona |
| Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients | NCT07153406 | Not yet recruiting | Phase 3 | 2025-09-15 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Pamplona |
At a glance
- 7 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| MDMA | 3 |
| DMT | 1 |
| Ayahuasca | 1 |
| Ketamine | 2 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 14% |
| Not yet recruiting | 1 | 14% |
| Completed | 3 | 43% |
| Status not reported | 2 | 29% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 3 | 43% |
| Phase 2 | 2 | 29% |
| Phase 3 | 1 | 14% |
| Not applicable | 1 | 14% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 2 |
| 2020 to 2023 | 3 |
| 2010 to 2014 | 1 |
| Before 2010 | 1 |
All counted studies
All 7 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression | NCT07422519 | Recruiting | Not applicable | 2025-09-18 | Hospital Universitari Vall d'Hebron Research Institute, Barcelona |
| Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients | NCT07153406 | Not yet recruiting | Phase 3 | 2025-09-15 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Pamplona |
| Abuse Potential and Human Pharmacology of Methylone | NCT05488171 | Status not reported | Phase 1 | 2021-12-01 | Germans Trias i Pujol Hospital, Badalona |
| Ayahuasca Assisted Psychotherapy for Grief | NCT06150859 | Status not reported | Phase 2 | 2021-10-15 | Beckley Med Foundation, Barcelona |
| Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification | NCT04003948 | Completed | Phase 2 | 2020-10-28 | International Center for Ethnobotanical Education, Research, and Service, Reus |
| Abuse Liability and Human Pharmacology of Mephedrone | NCT02232789 | Completed | Phase 1 | 2014-09-01 | Parc de Salut Mar, Barcelona |
| -Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms | NCT01447472 | Completed | Phase 1 | 2003-05-01 | Parc de Salut Mar, Barcelona |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
MDMA | DMT | Ayahuasca | Ketamine | Ibogaine
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 2 |
| Treatment-resistant depression | 2 |
| Opioid use disorder | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland